Skip to main content
. 2021 Dec 20;7(1):100357. doi: 10.1016/j.esmoop.2021.100357

Figure 3.

Figure 3

Difference in disease-free survival (DFS) (A) and overall survival (OS) (B) between circulating tumor DNA (ctDNA)-mutant group (MT) and ctDNA-wild-type group (WT) at 1 hour after surgery (T2).

Patients with mutant ctDNA BRAFV600E had shorter DFS (29 months versus median survival not reached, P = 0.001) and OS (median survival not reached in both groups, P = 0.003).